Hebei Kaiyou Biological Technology Co, Ltd

ADB-FUBINACA is a designer drug identified in synthetic rncannabis blends in Japan in 2013The enantiomer of ADB-FUBINACA is claimed in rnPfizer patent WO 2009/106982 and has been reported to be a potent agonist of the rnCB1 receptor and CB2 receptor with anEC50 value of 1.2 nM and 3.5 nM rnrespectively.ADB-FUBINACA features a carboxamide group at the 3-indazole rnposition, likeSDB-001 and STS-135. ADB-FUBINACA appears to be the product of rnrational drug design, since it differs from AB-FUBINACA only by the replacement rnof the isopropyl group with a tert-butyl group.

Systematic (IUPAC) name rn
N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide rn
Legal status
Legal status CA: Schedule II
DE: Anlage II rn(Prohibited)
 
Identifiers
CAS Number 1445583-51-6 
PubChem CID rn70969086
ChemSpider 29763706
UNII 05235E1S2O
Chemical data rn
Formula C21H23FN4O2
Molar mass 382.43 g/mol